Cargando…
Anti-angiogenic alternatives to VEGF blockade
Angiogenesis is a major requirement for tumour formation and development. Anti-angiogenic treatments aim to starve the tumour of nutrients and oxygen and also guard against metastasis. The main anti-angiogenic agents to date have focused on blocking the pro-angiogenic vascular endothelial growth fac...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761368/ https://www.ncbi.nlm.nih.gov/pubmed/26620208 http://dx.doi.org/10.1007/s10585-015-9769-3 |
_version_ | 1782416967048626176 |
---|---|
author | Khan, Kabir A. Bicknell, Roy |
author_facet | Khan, Kabir A. Bicknell, Roy |
author_sort | Khan, Kabir A. |
collection | PubMed |
description | Angiogenesis is a major requirement for tumour formation and development. Anti-angiogenic treatments aim to starve the tumour of nutrients and oxygen and also guard against metastasis. The main anti-angiogenic agents to date have focused on blocking the pro-angiogenic vascular endothelial growth factors (VEGFs). While this approach has seen some success and has provided a proof of principle that such anti-angiogenic agents can be used as treatment, the overall outcome of VEGF blockade has been somewhat disappointing. There is a current need for new strategies in inhibiting tumour angiogenesis; this article will review current and historical examples in blocking various membrane receptors and components of the extracellular matrix important in angiogenesis. Targeting these newly discovered pro-angiogenic proteins could provide novel strategies for cancer therapy. |
format | Online Article Text |
id | pubmed-4761368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-47613682016-03-01 Anti-angiogenic alternatives to VEGF blockade Khan, Kabir A. Bicknell, Roy Clin Exp Metastasis Review Angiogenesis is a major requirement for tumour formation and development. Anti-angiogenic treatments aim to starve the tumour of nutrients and oxygen and also guard against metastasis. The main anti-angiogenic agents to date have focused on blocking the pro-angiogenic vascular endothelial growth factors (VEGFs). While this approach has seen some success and has provided a proof of principle that such anti-angiogenic agents can be used as treatment, the overall outcome of VEGF blockade has been somewhat disappointing. There is a current need for new strategies in inhibiting tumour angiogenesis; this article will review current and historical examples in blocking various membrane receptors and components of the extracellular matrix important in angiogenesis. Targeting these newly discovered pro-angiogenic proteins could provide novel strategies for cancer therapy. Springer Netherlands 2015-11-30 2016 /pmc/articles/PMC4761368/ /pubmed/26620208 http://dx.doi.org/10.1007/s10585-015-9769-3 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Khan, Kabir A. Bicknell, Roy Anti-angiogenic alternatives to VEGF blockade |
title | Anti-angiogenic alternatives to VEGF blockade |
title_full | Anti-angiogenic alternatives to VEGF blockade |
title_fullStr | Anti-angiogenic alternatives to VEGF blockade |
title_full_unstemmed | Anti-angiogenic alternatives to VEGF blockade |
title_short | Anti-angiogenic alternatives to VEGF blockade |
title_sort | anti-angiogenic alternatives to vegf blockade |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761368/ https://www.ncbi.nlm.nih.gov/pubmed/26620208 http://dx.doi.org/10.1007/s10585-015-9769-3 |
work_keys_str_mv | AT khankabira antiangiogenicalternativestovegfblockade AT bicknellroy antiangiogenicalternativestovegfblockade |